Day 3

REDUCE-HTN: safety and efficacy of new bipolar device for renal denervation

solaci
solaci
389
0

This study included 146 patients with resistant hypertension who were medicated with an average of 5.4 drugs. Preliminary 18-month data showed a significant reduction of blood pressure values

Previous article
UK TAVI Registry: Long-term results of TAVI in the UK
Next article
SOURCE XT: Results at 2 years of SAPIEN XT valve
solaci
solaci

More articles by this author

SOURCE XT: Results at 2 years of SAPIEN XT valve

solaci - 0
Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at 2 years was 27.7%...

NOBORI II: Final 5-year results of drug-eluting stent with bio-absorbable polymer

solaci - 0
This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5...

TRYTON dedicated bifurcation stent in left main coronary artery

solaci - 0
TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral...

UK TAVI Registry: Long-term results of TAVI in the UK

solaci - 0
This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

SOURCE XT: Results at 2 years of SAPIEN XT valve

Multicenter prospective study included 2688 patients with a mean age of 81.4 years and 20.5 EuroScore. The all-cause mortality at...
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Dr. Juan Manuel Pérez - 0
Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Dr. Juan Manuel Pérez - 0
Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Dr. Juan Manuel Pérez - 0
Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...